[경제]SK Bioscience’s’Double Upper Limit’ … 28th in the market cap at once

[앵커]

In the first half of this year, SK Bioscience, which is known as a public offering and IPO, recorded a’double upper limit’ that rose to 160% of the public offering price immediately after listing.

As the KOSPI market cap ranking jumped to 28th at once, attention is focused on whether it will succeed in the upper limit for two days in a row.

The domestic stock market rose both on the KOSPI and on the KOSDAQ on the prospect that the US central bank, the Federal Reserve System, will further maintain zero interest rates.

Reporter Lee Jong-soo on the report.

[기자]

SK Bioscience, a vaccine specialized company that consigns AstraZeneca vaccines, has entered the KOSPI splendidly.

As soon as it was listed, the initial price was formed at 130,000 won, which is twice the public offering price of 65,000 won, and it immediately recorded the upper limit and soared to 169,000 won.

It succeeded immediately after listing at the’double upper limit’, which is 160% of the public offering price, and maintained the upper limit until the close of the market.

Accordingly, the market cap rose to 12.9 trillion won and jumped to 28th in the market cap, overtaking SK Biopharm and Big Hit, which were listed in popularity last year.

[김지하 / 메리츠증권 연구원 : 우선 SK바이오사이언스가 코로나19 백신을 위탁 생산하는 시행업체이기 때문에 밸류에이션 프리미엄을 받을 수 있다는 점 때문입니다. 두 번째 요인은 (보유 기간 제한 없는) 유통 가능 물량이 11.6%로 적다는 점인데요.]

Accordingly, the investor who received up to 7 weeks by putting 100 million won in the general public offering stock subscription earned more than 700,000 won.

SK Bioscience’s employee stock ownership members are believed to have been allocated an average of 7,484 shares per person, and the valuation gain per person is estimated to reach 780 million won.

There is also an interest in whether SK Bioscience will record the upper limit for two days in a row.

[김지하 / 메리츠증권 연구원 : 유통 물량이 적다는 점은 수급 면에서 좀 더 긍정적으로 작용할 것으로 보고 있습니다. 하지만 헬스케어 섹터 자체의 분위기가 작년과는 사뭇 다르다는 점, 그리고 현재 주식시장의 변동성이 매우 크다는 점을 고려할 필요가 있겠습니다.]

SK Bioscience’s brilliant debut, the KOSPI, rose 0.61% to 3,060 units.

Amid the prospect that the Federal Reserve System of the US Central Bank will further maintain zero interest rates, foreigners net bought over 480 billion won, leading the index to rise.

The KOSDAQ also climbed 0.64% from the battlefield and approached the 950 line.

YTN Jongsoo Lee[[email protected]]is.

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]